Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | CKS1B | P61024 | 2/20 | 0.50 |
| ▸ | SKP1 | P63208 | 2/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 7/20 | 0.48 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5916431 | 0.85 | ADK (0.56) | ADKGPR119MAP4K4CKS1BSKP1 | |
| SCHEMBL30546362 | 0.85 | PANK3 (0.63) | ADKGPR119MAP4K4CKS1BSKP1 | |
| SCHEMBL31286938 | 0.85 | GPR119 (0.56) | ADKGPR119MAP4K4CKS1BSKP1 | |
| SCHEMBL3554489 | 0.85 | PANK3 (0.63) | ADKGPR119MAP4K4CKS1BSKP1 | |
| SCHEMBL5916500 | 0.84 | GRM5 (0.57) | ADKGPR119MAP4K4CKS1BSKP1 | |
| SCHEMBL30906236 | 0.82 | ADK (0.54) | ADKGPR119MAP4K4CKS1BSKP1 | |
| SCHEMBL30906197 | 0.81 | ADK (0.56) | ADKGPR119MAP4K4CKS1BSKP1 | |
| SCHEMBL31464973 | 0.81 | CNR2 (0.59) | ADKGPR119MAP4K4CKS1BSKP1 | |
| SCHEMBL21522388 | 0.81 | CNR2 (0.59) | ADKGPR119MAP4K4CKS1BSKP1 | |
| SCHEMBL28981148 | 0.80 | CKS1B (0.46) | ADKGPR119MAP4K4CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153857-B2 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1417201-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003014111-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | ADK 4207/4885GPR119 776/4885MAP4K4 1795/4885 |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | ADK 4538/4885GPR119 1049/4885MAP4K4 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.